Platelet aggregation inhibition as adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA).
Contra Indication
:
Active internal bleeding (within 6 weeks), GI or GE bleeding of clinical significance, history of cerebrovascular accident (CVA) within 2 years or CVA with a significant neurological deficit, bleeding diathesis, administration of oral anticoagulant within 7 days unless prothrombin time is <1.2 times control, thrombocytopenia, recent major surgery or trauma, intracranial neoplasm, severe uncontrolled hypertension, presumed or documented history of vaculitis.
Caution
:
Free plasma concentration of the drug decreases rapidly with an initial half life of <10 min. and a second phase half life of 30 minutes. Platelet function recovers over the course of 48 hours.
Side Effect
:
Constipation, ileus, bleeding, thrombocytopenia, atrial fibrillation/flutter, complete AV block, palpitation, SVT, abnormal thinking, dizziness human antichimeric antibody development.
